Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | Is it feasible to use imaging modalities as an endpoint in myeloma clinical trials?

Elena Zamagni • 11 May 2023
COMy 2023
General Multiple Myeloma

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the possibility of using imaging modalities as an endpoint in myeloma clinical trials. Currently, imaging is systematically included in all prospective clinical trials, and Dr Zamagni comments on why it may not be feasible to tailor treatment exclusively on imaging alone. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elena Zamagni

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:23
Combining MRD assays with functional imaging in multiple myeloma
Elena Zamagni • 28 Sep 2023
1:21
The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial
Elena Zamagni • 28 Sep 2023
2:29
The role of various imaging techniques in multiple myeloma & the importance of optimizing these
Elena Zamagni • 28 Sep 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals